Constitutively activated signaling pathways contribute to the apoptosis-defect of B-CLL cells. Protein kinase C-d is a permanently activated kinase and a putative downstream target of phosphatidylinositol-3 kinase in B-CLL. Blockade of protein kinase C-d (PKC-d) by the highly specific inhibitor rottlerin induces apoptosis in chronic lymphocytic leukaemia (CLL) cells. By co-culturing bone marrow stromal and CLL cells, we determined that the proapoptotic effect of rottlerin is not abolished in the presence of survival factors, indicating that a targeted therapy against PKC-d might be a powerful approach for the treatment of CLL patients. The downstream events following rottlerin treatment engage mitochondrial and nonmitochondrial pathways and ultimately activate caspases that execute the apoptotic cell death. Herein we report that the inhibition of PKC-d decreases the expression of the important antiapoptotic proteins Mcl-1 and XIAP accompanied by a loss of the mitochondrial membrane potential Dw. In addition, we discovered that ZAP-70-expressing cells are significantly more susceptible to rottlerin-induced cell death than ZAP-70 negative cells. We finally observed that rottlerin can augment cell toxicity induced by standard chemotherapeutic drugs. Conclusively, PKC-d is a promising new target in the combat against CLL.
Introduction
In spite of a better understanding of their underlying molecular processes, most low-grade lymphomas still remain incurable. Recently, new antileukemic therapies are aimed at a blockade of specific signaling pathways involved in proliferation and apoptosis defects, rather than overwhelming cancer patients with cytotoxic chemotherapies lacking specification towards malignant cells. Obviously, both approaches do not exclude each other and synergistic effects combining standard chemotherapy and targeted therapies have already shown impressive clinical responses. 1, 2 Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world, characterized by an accumulation of mature B cells, incapable of undergoing appropriate cell death. Furthermore, B-CLL cells circulating in the peripheral blood are arrested in the G1-phase of the cell cycle and show a remarkable hypo-responsiveness towards most B-cell stimuli. 3 The relative benign course of the disease in a subset of patients and the initial chemosensitivity of CLL cells has contributed to little efforts in understanding the underlying molecular processes for a long time. Because CLL cells lack diseasespecific chromosomal translocations, a unique pathognomonic deregulation, such as BCR-Abl in CML cells, has not been found yet. Today, however, an increasing body of evidence has shown that the apoptotic defect of B-CLL cells is linked to constitutively activated signaling pathways: Schattner and co-workers 4 have first reported that the transcription factor nuclear factor-kappa B (NF-kB) is constitutively activated in B-CLL cells and contributes to the apoptotic defect and prolonged cell survival. Recently, we have discovered that the phosphatidylinositol-3 kinase (PI3-K) is also permanently active in quiescent CLL cells. LY294002, a small compound inhibiting PI3-K, is a strong apoptosis-inducer in CLL. Furthermore, we uncovered that the protein kinase C-d (PKC-d) is a downstream target of PI3-K and also constitutively activated in CLL cells. 5 Likewise, blockade of PKC-d induces apoptosis in malignant B cells, whereas normal peripheral B cells are unaffected by PKC-d inhibition.
In the present work, we have dissected the molecular events following inhibition of PKC-d in B-CLL cells and investigated its effects on different subsets of CLL cells.
Materials and methods

Cell samples
After informed consent, peripheral blood was obtained from at least 3-month untreated patients with a diagnosis of B-CLL. At the time of analysis, all patients were clinically stable, free from infectious complications and undergoing routine clinical outpatient review.
Separation procedures
Peripheral blood mononuclear cells (PBMNC) were isolated from heparinized blood samples by centrifugation over a FicollHypaque layer (Biochrom, Berlin, Germany) of 1.077 g/ml density. For separation of CLL B cells, PBMNC were incubated with anti-CD2 and anti-CD14 magnetic beads (Dynabeads M450, Dynal, Oslo, Norway) according to the manufacturer's instructions. After separation, B cells from CLL patients were 498% pure as assessed by direct immunofluorescence. Cells were harvested under ice-cold conditions and were cultured in RPMI 1640 (Biochrom) supplemented with 10% fetal calf serum (FCS) at 371C and 5% CO 2 in a fully humidified atmosphere.
Culture conditions
Purified B cells were cultured in RPMI 1640 medium (Biochrom) supplemented with 10% FCS (Biochrom), penicillin/strepto mycin 50 IU/ml, Na-pyruvate 1 mM, L-glutamine 2 mM, Lasparagine 20 mg/ml, 2-mercaptoethanol 0.05 mM, HEPES 10 mM and MEM non-essential amino acids 0.7 Â (Biochrom) at 371C and 5% CO 2 in a fully humidified atmosphere.
Reagents and antibodies
The PKC-d inhibitor rottlerin and the caspase inhibitor z.vad. fmk. was obtained from Calbiochem (Schwalbach, Germany). Monoclonal antibodies (mAb) specific for XIAP, Bcl-2, Bak, Bax, PKC-d and ZAP-70 were purchased from BD Transduction Laboratories (Heidelberg, Germany). Anti-phospho-PKC-d serine 643 and threonine 505 mAb were obtained from New England Biolabs (Schwalbach, Germany). An antibody against Mcl-1 was bought from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The chemotherapeutic agents vincristine, doxorubicin and fludarabine as well as FCCP were purchased from Sigma (Deisenhofen, Germany).
Bone marrow stromal cell cultures
After informed consent, bone marrows from normal volunteers were collected by bone marrow aspiration and BM-mononuclear cells were isolated by centrifugation over a FicollHypaque layer (Biochrom) of 1.077 g/ml density. Cells (2 Â 10 4 ) were plated in 24-well tissue plates in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 10% horse serum, 10 À4 mol/l, 2-mercaptoethanol, 1 mM sodium pyruvate, non-essential amino acids, 2 mM L-glutamine, 10 mM HEPES, 10 mg/ml L-asparagine, 100 U/ml penicillin/streptomycin and 10 À6 M hydrocortisone at 371C and 5% CO 2 in humidified air. The adhering cells were fed every week by complete replacement of the medium until a confluent layer had formed in each dish. Confluence usually was achieved after 4-6 weeks of culture.
Analysis of apoptosis
Cells were washed with phosphate-buffered saline (PBS) and resuspended in 500 ml binding buffer (Annexin V-FITC Kit, Immunotech) containing 1 ml of Annexin V-FITC stock and 5 ml of 20 mg/ml PI to determinate the PS exposure on the outer plasma membrane. After incubation for 10 min at room temperature, the specimens were quantified by flow cytometry, acquiring 5000 events.
The amount of fragmented DNA was assayed by a TdTmediated dUTP nick-end labelling (TUNEL) (Boehringer Mannheim, Indianapolis, IN, USA): Cells (10 5 ) per sample were washed in PBS and fixed in 2% paraformaldehyde for 30 min at room temperature. After fixation, the cells were washed twice in PBS supplemented with 0.01% bovine serum albumin (BSA). Afterwards, cells were resuspended in TUNEL reaction buffer, containing fluorescein dUTP and TdT. Fluorescein incorporated in DNA strand breaks was detected by flow cytometry.
Immunoblotting
To investigate cell proteins via Western blot, 1 to 10 Â 10 7 cells were lysed in lysis buffer (10 mM Tris/HCl (pH 7.4), 5 mM EDTA, 130 mM NaCl, 1% Triton, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na 3 VO 4 and 10 mg/ml of each phenantroline, aprotinin, leupeptin and pepstatin) for 20 min at 41C. Lysates were spun at 12 000 r.p.m. for 20 min and supernatants were collected. Protein concentration was assessed by the Bio-Rad assay method (Bio-Rad Laboratories, Richmond, Canada). Total extracts (40 mg/lane) were subjected to SDS-PAGE and blotting was performed on PVDF membranes (Immobilon-P, Millipore GmbH, Germany).
Investigation of the mitochondrial membrane potential
The mitochondrial membrane potential Dc was studied by flow cytometric analysis of the fluorescence 3,3 0 -dihexyloxacarbocyanine iodide (DiOC6(3)) as reported elsewhere. 6 ATP assay 1 Â 10 6 cells/ml medium were incubated with 5 mM rottlerin, 10 mM FCCP or kept in medium alone. ATP was extracted as described elsewhere. 7 Briefly, cells were spun at 2000 UPM before lysed with proteinase K in HEPES buffer, pH 7.4. After 15 min of incubation at 501C, proteinase K was heat-inactivated at 801C and cell lysates were frozen in liquid nitrogen. The ATP content was determined by using an ATP-Determination-kit according to the manufacturer's instruction's (Molecular Probes, Eugene, OR, USA).
ZAP70 expression
For determination of ZAP70 expression, Western blots included total cellular extracts from a mantle cell lymphoma cell line (NCEB) and a T-cell lymphoma cell line (Jurkat) as a negative and positive control, respectively.
Electrophoretic mobility shift assay
Nuclear extracts were prepared and analyzed as described elsewhere. 8 The binding of NF-kB was determined by electrophoretic mobility shift assay (EMSA) using specific consensus oligonucleotides (Promega, Heidelberg, Germany) labelled with 20 mCi (0.37 MBq) [g- 32 P] ATP and T4 polynucleotide kinase (Boehringer Mannheim). Nuclear extracts (5 mg of protein) were incubated with radiolabelled DNA probes (B10 ng) for 30 min at room temperature in 20 ml of binding buffer (20 mM HEPES, pH 7.9, 59 mM KCl, 1 mM dithiothreitol, 0.5 mM EDTA, 10% glycerol, 1 mg/ml BSA, 0.2% Nonidet P-40,50 ng of poly(dI-dC)/ ml). Samples were run in 0.25 Â TBE buffer (10 Â TBE is as follows: 890 mM Tris, 890 mM boric acid, 20 mM EDTA, pH 8.0) on nondenaturing 4% polyacrylamide gels. Gels were dried and analyzed by autoradiography. Supershifts were performed by the addition of 2 mg mAb against p50-NF-kB to the nuclear extracts.
Statistical analysis
Data from individual experiments are presented as mean7 s.e.m. Statistical significances were determined using the Wilcoxon signed rank test and the Mann-Whitney test as appropriate. A P-value o0.05 was considered to be statistically significant.
Results
Rottlerin-induced apoptosis of B-CLL cells overcomes stroma-cell mediated antiapoptotic signals
The apoptotic defect in CLL cells is not a cell-autonomous process but is heavily dependent on survival factors derived from bone marrow stromal cells: B-CLL cells cultured in medium supplemented with FCS alone rapidly undergo spontaneous apoptosis, whereas when co-cultured with bone marrow stroma cells, CLL cells survive for several weeks. 9 This interaction is based on direct cell-cell interactions and soluble factors secreted by CLL cells and stromal cells. 10 To determine whether the proapoptotic effect induced by rottlerin is antagonized by survival factors derived from allogenic bone marrow stromal cells, we compared apoptotic levels between cells cultured in medium/FCS or cultured on BM stromal cells. One representative experiment out of three is shown in Figure 1 . The percentage of apoptotic cells was measured by staining with Annexin-V and PI after the indicated time. In accordance with published data, co-cultured stromal cells can protect CLL cells from spontaneous apoptosis in vitro (white bars). Interestingly, the proapoptotic effect mediated by a blockade of PKC-d is not antagonized by stromal cells survival factors (black bars). These results support the idea that a targeted therapy against PKC-d might have a therapeutic effect in vivo.
Rottlerin modulates the expression of apoptosisregulating proteins
Dysfunctional apoptosis has been related to an overexpression of antiapoptotic proteins in B-CLL cells. Several apoptosisregulating proteins, such as Bcl-2, are commonly constitutively overexpressed in circulating cells and disrupt the mitochondrial apoptotic function. Likewise, high expression levels of the Bcl-2 family member Mcl-1 have been associated with a failure to achieve complete remissions to chemotherapy. 11 However, the net-outcome of bcl-2 family proteins acting on the mitochondria is dependent on the balance of pro-and antiapoptotic proteins. 12 We determined the protein levels of several Bcl-2 family proteins in the absence or presence of rottlerin (5 mM) by using antibodies specific for Bcl-2, Mcl-1, Bax, Bak and XIAP. Protein expression was followed by immunoblot assay over the time course of 24 h (Figure 2 ). The antiapoptotic protein Mcl-1 is constitutively highly expressed in CLL cells and expression level spontaneously decreased during in vitro culture of cells. However, inhibition of PKC-d strongly downregulates Mcl-1 expression after 12 h, whereas its expression becomes undetectable after 24 h. XIAP, a member of the inhibitor of apoptosis (IAP) family, can directly bind to and suppress several caspases. 13 Like Mcl-1, XIAP expression is markedly reduced by blocking PKC-d activity, but remains stable in cells cultured in medium alone. In addition to changes in Mcl-1-and XIAP-levels, the expression of the proapoptotic proteins Bak and Bax were also effected by PKC-d inhibition. Both proteins act on the mitochondria and counterbalance bcl-2. Bak protein can hardly be detected in resting CLL cells in vitro, whereas its expression increases upon rottlerin treatment. Likewise, inhibition of PKC-d resulted in a decrease of full-length Bax and an increase in the 18 kDa cleavage product of Bax (Figure 2 ). In contrast, the protein expression of Bcl-2 remained stable regardless of PKC-d inhibition. Most likely the modulation of Bak and Bax because of rottlerin treatment is not a nonspecific effect: flavopiridoltreated CLL cells significantly undergo apoptosis without changes in Bak and Bax levels. 14 
PKC-d inhibition activates caspases
To further characterize rottlerin-induced cell death in CLL cells, we investigated the activation of caspases upon treatment with the PKC-d inhibitor. Caspases are a family of cysteine-aspartic acid proteases that play an important role in the activation and propagation of death signaling. Activation of initiator-caspases (caspase-8, -9 and -10) leads to the proteolytic activation of downstream effector caspases (caspase -3, -6 and -7). Two independent pathways, death receptors and the mitochondria, lie upstream of caspase activation.
In order to confirm the dependence of rottlerin-induced cell death on caspases, we tested the impact of the pan-caspase inhibitor z.vad.fmk on CLL cells. B-CLL cells were either incubated in medium/FCS alone, medium supplemented with z.vad.fmk (100 mM), rottlerin or a combination of both (Figure 3a) . Apoptotic cells were detected by Annexin-V/PI or TUNEL staining. In accordance with previous publications, z.vad.fmk was able to inhibit spontaneous apoptosis of CLL cells cultured in vitro (Figure 3a, panel 2) . Rottlerin-induced apoptosis was almost completely abolished in the presence of the pan-caspase inhibitor. These data indicate a strong dependence of rottlerin-induced cell death on caspase activity. 
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Apoptosis is accompanied by the disintegration of the mitochondria, which ultimately leads to a release of cytochrome c. The mitochondrial membrane potential can be analyzed by staining with the lipophilic, cationic, fluorescent probe DiOC6(3). Because the dye uptake is driven by Dc, mitochondrial function can easily be measured by flow cytometry. Cells were either incubated in medium/FCS (Figure 3b, left panel) or in medium/FCS supplemented with rottlerin 5 mM (Figure 3b , right panel). After 24 h, DiOC6(3) was added to the culture 10 min before analyzing the samples. Treatment of cells with rottlerin significantly diminished the mitochondrial membrane potential Dc, indicating that mitochondrial dysfunction is involved in rottlerin-induced cell death.
However, a recent publication has reported that rottlerin rapidly reduces ATP levels by uncoupling the mitochondrial respiration from oxidative phosphorylation without the requirement of PKC-d. 15 To evaluate a direct effect of rottlerin on the mitochondria, we measured ATP levels in B-CLL cells shortly after exposure to rottlerin. We did not observe a significant decrease in ATP levels in B-CLL cells after 15 min of rottlerin treatment (91.378.3% compared to medium control) while treatment with FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone) led to a reduction in ATP levels, which were reduced to 74.7% (75.9%) compared to cells kept in medium alone (Figure 3c ). FCCP is an uncoupler of oxidative phosphorylation and depolarizes the mitochondrial membrane. Conclusively from these data, we presume that rottlerin-induced apoptosis is not directly linked to an impairment of the mitochondrial respiration. However, resting CLL cells seem to have a low consumption of ATP as compared to other cell types.
Increased sensitivity of ZAP-70-positive cells towards rottlerin-induced apoptosis
CLL is a disease with a very heterogeneous outcome. In general, two subgroups of CLL patients can be distinguished based upon the mutational status of IgVH genes. Patients with unmutated IgVH genes are more likely to develop progressive disease within a shorter time than patients with mutated IgVH genes. 16 Recently, gene expression profile studies have revealed another 
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surrogate marker for disease progression: ZAP-70 is an enzyme usually expressed in T cells, where it is involved in T-cell receptor signaling. A subset of B-CLL cells aberrantly expresses ZAP-70. Interestingly, the expression of ZAP-70 is limited to CLL cells with unmutated IgVH genes, predicting a poorer prognosis and early disease progression. 17 We sought to investigate whether the ZAP-70 expression status affects the responsiveness towards rottlerin-induced apoptosis. ZAP-70 expression was measured by Western blotting as described in Materials and methods. Cells were incubated in medium/10% FCS alone or in the presence of rottlerin (5 mM). After 24 h the number of apoptotic cells was measured by Annexin-V/PI staining. As shown in Figure 4a , the apoptotic response to rottlerin was significantly higher in B-CLL cells expressing ZAP 70 compared to ZAP 70 negative cells (P ¼ 0.006). Therefore, patients with an unfavourable prognosis might have a greater benefit from a targeted therapy against PKC-d.
This result prompted us to investigate if differences in the expression levels of PKC-d contribute to the increased susceptibility of ZAP-70 positive cells to rottlerin-induced cell death. To address this question, we analyzed protein levels of PKC-d in freshly isolated CLL cells by immunoblotting. We found that PKC-d levels were similar in all CLL cells investigated, regardless of their ZAP-70 expression (Figure 4b) . However, like other PKC-isoforms, the activity of PKC-d is determined by posttranslational modifications, mainly phosphorylation on serine/ threonine residues. Phosphorylation of threonine 505 at the activation loop increases PKC-d activity 18 and is a putative phosphorylation site for PDK-1, downstream of PI-3 kinase. 19 Because PI-3 kinase is constitutively activated in CLL cells, 5 we considered that phosphorylation on threonine 505 could indicate variations in PI-3 kinase activity in the different subsets of CLL cells. Furthermore, like many other kinases, PKC-d undergoes auto-phosphorylation: Threonine-643 is an in vitro phosphorylation site for PKC-d and appears to be critical for enzymatic activity. 20 By using phospho-specific antibodies, we did not detect any significant difference in threonine 505-or threonine 643-phosphorylation between ZAP-70 positive and negative cells (Figure 4b ). It is worthwhile mentioning that rottlerin treatment does not effect the phosphorylation of PKC-d on these putative phosphorylation sites (Supplementary Figure 1) .
However, in spite of its equal expression in the two subgroups of cells, expression differences in PKC-d downstream targets could contribute to the increased apoptotic response in ZAP-70 positive cells.
The transcription factor NF-kB is constitutively activated in B-CLL and is engaged in antiapoptotic signaling pathways, such as CD40-and BCR-ligation. 4, 21 In accordance with data showing that PKC-d can activate NF-kB in several cell types, 22, 23 we found that NF-kB is also a conduit for PKC-d in B-CLL cells (unpublished data). This prompted us to investigate whether higher constitutive expression levels of NF-kB in ZAP-70-expressing cells could explain the stronger apoptotic response after rottlerin treatment. To test this hypothesis, we compared NF-kB activation of ZAP-70 positive and negative cells by EMSA. We observed an equal expression of NF-kB in both subgroups, without a significant difference between ZAP-70 positive and negative cells (Figure 4c) .
We conclude that, in spite of a significant stronger apoptotic response of ZAP-70 positive cells, expression level and activation of PKC-d and NF-kB are similar in ZAP-70-expressing and non-expressing cells.
Inhibition of PKC-d synergizes with chemotherapyinduced apoptosis
Synergistic effects have been described between protein-kinase inhibitors and standard chemotherapies for several different tumor entities. We analyzed whether inhibition of PKC-d by rottlerin could increase chemotherapy-induced apoptosis of B-CLL cells.
CLL cells were incubated in medium supplemented with rottlerin (5 mM) and vincristine (100 ng/ml), doxorubicin (300 ng/ ml) or fludarabine (1 mg/ml). We have chosen these drugs for our in vitro experiments because they are frequently used for the treatment of CLL patients and have shown activity against malignant B cells in vivo. After 48 h, the percentage of apoptotic cells was measured by flow-cytometry using Annexin-V/PI stains. Figure 5 shows that the combination of vincristine and rottlerin significantly augments the number of dead cells compared to single-agent treatment (P ¼ 0.007). In contrast to vincristine, no synergistic effect was observed using a combination of doxorubicin and rottlerin (P ¼ 0.89). Fludarabineinduced cytotoxicity was also enhanced upon treatment with the PKC-d inhibitor, but no statistical significance was observed (P ¼ 0.31). In summary, blockade of PKC-d by rottlerin has synergistic effects with vincristine and a combined therapy can augment apoptosis compared to a single-agent treatment.
Discussion
Encouraged by our previous finding that PKC-d is constitutively activated in B-CLL cells and obviously involved in the defect of undergoing apoptosis, 5 we sought to investigate the molecular events following inhibition of PKC-d in order to determine whether the aberrantly activated kinase is a potential target for the treatment of CLL patients.
Rottlerin, a compound from Mallotus philippinensis, is a widely used inhibitor for PKC and has shown to block PKC-d specifically if used in concentrations as low as 10 mM.
24
Treatment of CLL cells with rottlerin induces apoptosis exclusively in malignant B cells, whereas normal peripheral B cells are resistant to rottlerin-induced cell death. 5 Interestingly, the proapoptotic effect of rottlerin was not abolished in the presence of stroma-cell-derived survival factors, indicating that PKC-d might play an essential role in the survival of CLL cells and cannot be bypassed by survival signals. We have further demonstrated that shutting down the constitutive activity of PKC-d results in a strong apoptotic response of CLL cells, primarily by affecting the expression of proteins acting on the mitochondria (Figure 2 ). Higher expression levels of Mcl-1 contribute to the longevity of malignant B cells and correlate with a resistance to chemotherapy.
11 Surprisingly, little is known about the mechanisms of upregulation of Mcl-1 in CLL. While PKC-d controls various transcription factors, such as SP-1 25 and AP-1, 26 Mcl-1 downregulation following rottlerin treatment is most likely related to a transcriptional repression of the gene. However, translational regulation of Mcl-1 expression during apoptosis has been reported 27 and might also contribute to the decay of Mcl-1 after exposure to rottlerin. In addition to a decrease of Mcl-1 protein upon treatment with rottlerin, XIAP levels decline rapidly after inhibition of PKC-d. PKC has also been reported to act upstream of inhibitors of apoptosis family members (IAPs), through a mechanism that involves NF-kB activation. 28 Remarkable, in spite of a strong apoptotic response to rottlerin, bcl-2 levels remained unchanged, indicating that overexpressed bcl-2 by itself is not sufficient to maintain the apoptotic defect of CLL cells. Conclusively, PKC-d seems to act upstream of the mitochondrial compartment. Blockade of its constitutive activity downregulates antiapoptotic proteins and unleashes the apoptotic machinery.
Nowadays, the best prognostic prediction in B-CLL at an early clinical stage is based on the immunoglobulin variable heavy chain gene (IgVH) mutation status. The aberrant expression of the T-cell antigen ZAP-70 correlates with an un-mutated IgVH status and therefore has become a surrogate marker for high-risk CLL patients. Surprisingly, we have observed an increased susceptibility of ZAP-70-expressing cells towards rottlerin, resulting in a stronger apoptotic response in comparison to ZAP-70 negative B-CLL cells (Figure 4a ). Nonetheless, we did not find any significant difference between these two subgroups, neither in the expression level nor in PKC-d phosphorylation, which could explain this conundrum. Several possibilities have to be taken into consideration to interpret this result: (Figure 4c ). However, this does not exclude the existence of other PKC-d target proteins, which are differently expressed depending on the maturation status of the malignant cell population. (3) We finally cannot completely rule out that rottlerin-induced apoptosis is independent of PKC-d and relies on blockade of an unknown target. In contrast to a report that rottlerin reduces ATP levels by directly uncoupling the mitochondrial respiration from oxidative phosphorylation in parotid acinar cells, 15 we did not observe a significant change in ATP levels after rottlerin treatment of B-CLL cells (Figure 3c ). This contradiction is most likely because of different energy-dependent processes in different cell types and the quiescent state of G1-arrested CLL cells may not require much ATP. However, the blockade of PKC-d mimics the inhibition of the constitutively activated PI-3 kinase and this supports the hypothesis that rottlerin-induced apoptosis is indeed because of a specific blockade of PKC-d.
We finally report that inhibition of PKC-d synergizes with vincristine-induced cytotoxicity ( Figure 5 ). This effect was not observed in combinations of rottlerin and doxorubicin or fludarabine. All of these drugs are widely used in combination chemotherapy regimes for the treatment of CLL patients, but their mechanism of action is different: The cytotoxic effects of vincristine have been related to tubulin inhibition, thereby blocking progression through the M-phase of the cell cycle. In contrast, doxorubicin and fludarabine act through the p53 pathway 29 and through blocking DNA synthesis. 30 Vilpo et al 31 have reported that vincristine has a single-agent activity against CLL cells in vitro. Although the majority of CLL cells are mitotically inactive, other effects than blocking mitosis must be responsible for its cytotoxicity against CLL. Understanding the mechanisms involved can shed light on the synergistic effect between vincristine and inhibition of PKC-d. Activation of PKC has been reported to promote vincristine efflux and drug resistance in a T-ALL cell line. 32 Whether PKC-d plays a role in drug resistance in CLL is currently in the focus of our work and will help us to better understand the molecular functions of aberrantly expressed protein kinases in the pathogenesis of CLL.
In conclusion from our work, a targeted therapy against PKC-d seems to be an alternative and interesting new approach to improve the treatment of patients with CLL.
